Clinical Trials Browser

Interventional × rucaparib × Clear all

NCT03617679 2026-02-23

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Phase 2 Active not recruiting

79 enrolled 12 charts

Endometrial Neoplasms

NCT03559049 2026-02-12

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Phase 1/2 Terminated

25 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

Phase 2 Completed

292 enrolled 21 charts

Prostatic Neoplasms

NCT03542175 2025-12-08

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

Phase 1 Completed

31 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04276376 2025-12-01

ARIANES

Phase 2 Terminated

Other solid neoplasm

Solid Tumor

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT03522246 2025-06-24

ATHENA

Phase 3 Active not recruiting

1,097 enrolled 26 charts

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Phase 2 Terminated

ATM Gene Mutation

NCT02678182 2025-06-10

PLATFORM

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma of the Oesophagus

NCT02873962 2025-06-08

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03639935 2025-06-03

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Phase 2 Completed

32 enrolled 14 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT03694262 2025-05-30

EndoBARR

Phase 2 Active not recruiting

30 enrolled 7 charts

Endometrial Neoplasms

NCT03845296 2025-05-21

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2 Completed

64 enrolled 17 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04253262 2025-05-04

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Phase 1/2 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT04209595 2025-03-17

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

Phase 1/2 Completed

10 enrolled 13 charts

Small Cell Lung Carcinoma

NCT03552471 2025-02-13

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04826198 2024-12-05

REVOCAN

Phase 1/2 Terminated

Ovarian Neoplasms

NCT03958045 2024-10-22

Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

Phase 2 Completed

33 enrolled 15 charts

Small Cell Lung Carcinoma

NCT03413995 2024-10-16

TRIUMPH

Phase 2 Completed

12 enrolled 11 charts

Prostate Cancer Metastatic

NCT03911453 2024-10-03

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT01074970 2024-09-19

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Phase 2 Completed

135 enrolled 14 charts

Breast Neoplasms

NCT03337087 2024-05-17

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Phase 1/2 Active not recruiting

18 enrolled 12 charts

Gastrointestinal

Gastrointestinal Neoplasms, Colorectal Neoplasms

NCT03533946 2024-03-13

ROAR

Phase 2 Terminated

7 enrolled 10 charts

Prostatic Neoplasms

NCT03476798 2024-02-15

Clovis-001

Phase 2 Completed

49 enrolled 13 charts

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT03840200 2023-10-30

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Phase 1 Completed

51 enrolled 20 charts

BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT04171700 2023-10-02

LODESTAR

Phase 2 Terminated

83 enrolled 16 charts

BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03140670 2023-09-28

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Phase 2 Terminated

46 enrolled 16 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04179396 2023-06-29

RAMP

Phase 1 Completed

8 enrolled 8 charts

Metastatic Castration Resistant Prostate Cancer

NCT02042378 2023-06-13

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT03824704 2023-06-12

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

Phase 2 Terminated

1 enrolled 7 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Carcinoma, Endometrioid

NCT01482715 2023-06-09

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Phase 1/2 Completed

136 enrolled 30 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT01968213 2023-06-09

ARIEL3

Phase 3 Completed

564 enrolled 18 charts 1 FDA

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Phase 3 Completed

349 enrolled 29 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT02935634 2023-06-09

FRACTION-GC

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

NCT02952534 2023-06-09

TRITON2

Phase 2 Completed

277 enrolled 23 charts 2 FDA

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related

NCT03397394 2023-06-09

ATLAS

Phase 2 Terminated

97 enrolled 12 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03499444 2023-06-09

A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT03521037 2023-06-09

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

Phase 1 Completed

Neoplasms

NCT01009190 2023-06-08

A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT03954366 2023-06-08

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

Phase 1 Completed

Neoplasms

NCT03654833 2023-03-14

MiST

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03995017 2023-02-01

RiME

Phase 1/2 Unknown

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Stomach Neoplasms

NCT03462212 2021-08-27

MITO25

Phase 1/2 Unknown

Fallopian Tube Neoplasms

NCT02505048 2021-06-08

RUBY

Phase 2 Completed

Breast Neoplasms

NCT03572478 2021-03-09

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

GenitourinaryGynecologic

Prostatic Neoplasms, Endometrial Neoplasms

NCT03101280 2020-10-22

A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Phase 1 Completed

Genital Neoplasms, Female

NCT03795272 2019-11-01

MaRuC

Phase 2 Withdrawn

Uterine Cervical Neoplasms

NCT00664781 2016-05-24

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Phase 2 Completed

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Ovarian Neoplasms